Clinical trials · Chicago, IL
Systemic Lupus Erythematosus clinical trials in Chicago
We’re tracking 19 recruiting systemic lupus erythematosus studies with a site in or near Chicago — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Chicago
- NCT06661213Enrolling by invitationEarly Phase 1
Tapinarof cream for lupus skin lesions
This study tests if a cream called tapinarof can improve skin symptoms in people with chronic or subacute cutaneous lupus erythematosus (CLE). The goal is to see if it reduces redness, scaling, and thickness of active lesions.
Chicago, IllinoisAges 18 years+ - NCT05934149Recruiting
Lupus health registry that stores samples for future research
This study keeps a long-term record of people with lupus (systemic lupus erythematosus) and collects samples so researchers can study the disease better. You may be able to join if you meet lupus diagnosis criteria, are not pregnant, and can follow the study visits and consent process.
Chicago, IllinoisAges 18–110 - NCT06617325RecruitingPhase 3
New drug for moderate to severe lupus
This study tests a new medicine called Dapirolizumab Pegol (given as an infusion) for people with moderate to severe lupus (SLE) that is not well controlled despite standard treatments. It aims to see if the drug can reduce lupus activity and prevent flares.
Chicago, IllinoisAges 16 years+ - NCT07691970RecruitingPhase 3
Continued treatment study for people who benefited from anifrolumab
This study lets people who finished a previous anifrolumab (Saphnelo) trial and saw benefits continue getting the treatment. It aims to see how well the drug works over a longer time.
Chicago, IllinoisAges 5–80 - NCT05835310RecruitingPhase 3
IV anifrolumab for active lupus in children
This study tests whether an intravenous medicine called anifrolumab can safely improve active systemic lupus (SLE) in children. If you qualify, you may receive the study treatment and be closely monitored for safety and lupus symptoms.
Chicago, IllinoisAges 5–17 - NCT06925542RecruitingPhase 1
Study of CTX112 for adults with autoimmune disease
This trial tests an experimental cell therapy called CTX112 for people with lupus, scleroderma, or inflammatory myositis that hasn't responded well to standard treatments. The goal is to see if it's safe and if it can help control the disease.
Chicago, IllinoisAges 18–70 - NCT06121297RecruitingPhase 1/Phase 2
CABA-201 treatment for systemic lupus erythematosus
This study tests a new treatment called CABA-201 for people with active systemic lupus erythematosus (SLE). The treatment aims to reduce disease activity and may help those who haven't responded well to other treatments.
Chicago, IllinoisAges 12–65 - NCT06897930RecruitingPhase 1/Phase 2
Testing a new drug for adults with lupus
This trial tests an investigational drug called AZD0120 in adults with lupus that hasn't improved with standard treatments. The goal is to see if it's safe and works well for people with lupus-related organ problems.
Chicago, IllinoisAges 18–70 - NCT04976322Enrolling by invitationPhase 3
Long-term lupus treatment safety study with dapirolizumab
This Phase 3 study tests whether dapirolizumab pegol is safe and tolerable for people with systemic lupus erythematosus (SLE) when taken long-term. You may be offered a chance to stay on this medicine if the study team thinks you could benefit.
Chicago, IllinoisAges 16 years+ - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune disease
This trial tests whether the immunotherapy drug nivolumab can safely treat advanced cancer in people who also have an autoimmune disease like rheumatoid arthritis, lupus, or multiple sclerosis. It aims to find out if the drug may help control cancer while managing their autoimmune condition.
Chicago, IllinoisAges 18 years+ - NCT00198068Recruiting
Study pregnancy outcomes in lupus and antiphospholipid syndrome
This study looks for factors that may predict how pregnancy turns out in people with lupus (SLE) and/or antiphospholipid syndrome (APS). It may help doctors better understand what to monitor in early pregnancy to support healthier outcomes.
Chicago, IllinoisAges 18–45 - NCT07085104RecruitingPhase 1
Study of ALLO-329 for lupus, myositis, or scleroderma
This trial tests a new one-time cell therapy (ALLO-329) made from donor cells to target and calm overactive immune cells in people with lupus, myositis, or scleroderma that hasn't improved with usual medications. It aims to see if this treatment is safe and can help reduce disease activity.
Chicago, IllinoisAges 18–74 - NCT07328581RecruitingPhase 2
CAR-T cell therapy for refractory lupus with or without kidney involvement
This trial tests a new treatment called ICG318 CAR-T, which uses your own immune cells to target and calm the overactive immune system in lupus. It may help people whose lupus has not improved with standard treatments, including those with lupus nephritis (kidney inflammation).
Chicago, IllinoisAges 16–70 - NCT06133972RecruitingPhase 3
Long-term safety of ianalumab for lupus (extension study)
This extension study tests the long-term safety of ianalumab for people with systemic lupus erythematosus. If you completed a prior SIRIUS-SLE study and your doctor thinks you'd benefit, you may continue treatment for up to 60 more weeks.
Skokie, IllinoisAges 12–100 - NCT07430306RecruitingPhase 3
Study of anifrolumab for lupus patients not yet on strong treatments
This trial tests if a new drug called anifrolumab can help treat lupus in people who haven't taken strong medications like biologics or immunosuppressants before. It looks at overall disease activity and the chance to reduce steroid use.
Willowbrook, IllinoisAges 18–70 - NCT07438496RecruitingPhase 3
Study of nipocalimab for moderate to severe lupus
This trial tests a new medicine, nipocalimab, for adults with moderate to severe lupus. It aims to see if the drug can help control lupus symptoms and reduce disease activity.
Willowbrook, IllinoisAges 18–75 - NCT07175285Recruiting
Study for lupus patients not helped by steroids and 2 immunosuppressants
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
Willowbrook, IllinoisAges 16 years+ - NCT07607964RecruitingPhase 1
ABBV-519 Study for Lupus or Rheumatoid Arthritis
This early-stage trial tests a new drug called ABBV-519 given as infusions or injections to treat systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) in adults whose disease hasn't responded well to other treatments. Researchers will measure how safe the drug is, how it moves through your body, and whether it helps reduce symptoms.
Orland Park, IllinoisAges 18–75 - NCT06977724RecruitingPhase 1
Testing a new drug for lupus, sjogren's, and rheumatoid arthritis
This study tests an experimental medicine given by IV infusion to see if it is safe and helps reduce symptoms of lupus, sjogren's disease, or rheumatoid arthritis. It is an early-phase trial, so the main goals are checking side effects and how the drug behaves in the body, but it will also look at how well it works.
Orland Park, IllinoisAges 18–75
Hear when a new Systemic Lupus Erythematosus trial opens near Chicago, IL
We’ll email you when one opens near Chicago, IL — at most once a week, no account needed, unsubscribe anytime.
Systemic Lupus Erythematosus trials in other cities
Where these studies are running near Chicago
Institutions with a site for the recruiting systemic lupus erythematosus studies listed above.
- Northwestern University · 4 studies
- Research Site · 4 studies
- University of Chicago · 3 studies
- Advanced Quality Medical Research /ID# 278462
- Advanced Quality Medical Research /ID# 279147
- Clinic of Robert Hozman
- Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center
- Sl0044 50699
What taking part in a systemic lupus erythematosus study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting systemic lupus erythematosus studies in Illinois.
Common questions
- Are there systemic lupus erythematosus clinical trials near Chicago?
- Yes. We're currently tracking 19 recruiting systemic lupus erythematosus studies with a site near Chicago, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a systemic lupus erythematosus study near Chicago?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Chicago to take part?
- Not necessarily. These studies have a site near Chicago, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a systemic lupus erythematosus trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New systemic lupus erythematosus studies open near Chicago regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.